Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Kappelhoff · SciRah

Researcher profile · Semantic Scholar

B. Kappelhoff

Share profile

B. Kappelhoff — researcher profile on SciRah

h-index: 12
Works: 29
Citations: 910

Most-cited papers

Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?
B. Kappelhoff, F. van Leth, P. Robinson, T. Macgregor +8 more
2005Antiviral Therapy167 citations Open access
Semantic Scholar
The relationship between cognition and functioning in schizophrenia: A semi-systematic review
S. Kharawala, C. Hastedt, J. Podhorná, Hemlata Shukla +2 more
2021Schizophrenia Research: Cognition135 citations Open access
Semantic Scholar
Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study
B. Kappelhoff, F. van Leth, T. Macgregor, J. Lange +2 more
2005Antiviral Therapy115 citations
Semantic Scholar
Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs
B. Kappelhoff, K. Crommentuyn, M. D. de Maat, J. Mulder +2 more
2004Clinical Pharmacokinetics111 citations
Semantic Scholar
Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy
F. van Leth, B. Kappelhoff, D. Johnson, M. H. Losso +9 more
2006AIDS Research and Human Retroviruses81 citations
Semantic Scholar
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
K. Crommentuyn, B. Kappelhoff, J. Mulder, A. Mairuhu +4 more
2005British Journal of Clinical Pharmacology71 citations Open access
Semantic Scholar
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
B. Kappelhoff, H. Rosing, A. Huitema, J. Beijnen
2003Journal of chromatography. B, Analytical technologies in the biomedical and life sciences59 citations
Semantic Scholar
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
B. Kappelhoff, A. Huitema, K. Crommentuyn, J. Mulder +4 more
2005British Journal of Clinical Pharmacology37 citations Open access
Semantic Scholar
Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study
B. Kappelhoff, A. Huitema, F. van Leth, P. Robinson +3 more
2005HIV Clinical Trials29 citations Open access
Semantic Scholar
Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals
B. Kappelhoff, A. Huitema, Z. Yalvaç, J. Prins +3 more
2005Clinical Pharmacokinetics23 citations
Semantic Scholar
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
B. Kappelhoff, A. Huitema, S. Sankatsing, P. Meenhorst +4 more
2005British Journal of Clinical Pharmacology16 citations Open access
Semantic Scholar
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands
M. Postma, B. Kappelhoff, M. van Hulst, J. Brouwers
2012Journal of Medical Economics12 citations Open access
Semantic Scholar
Cost Effectiveness and Resource Allocation Cost-effectiveness of Tipranavir versus Comparator Protease Inhibitor Regimens in Hiv Infected Patients Previously Exposed to Antiretroviral Therapy in the Netherlands
Gijs Aa Hubben, J. Bos, Christa A. Veltman-Starkenburg, Simon Stegmeijer +10 more
200712 citations
Semantic Scholar
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
J. Stevanović, De L. A. Jong, B. Kappelhoff, E. Dvortsin +2 more
2016PLoS ONE10 citations Open access
Semantic Scholar
Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
M. Hoogendoorn, B. Kappelhoff, J. Overbeek, Emiel F. M. Wouters +1 more
2012Netherlands Journal of Medicine10 citations
Semantic Scholar
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
M. van Hulst, J. Stevanović, M. Jacobs, R. Tieleman +2 more
2018Journal of Medical Economics6 citations Open access
Semantic Scholar
Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism.
J. Stevanović, B. Kappelhoff, M. Voorhaar, M. Postma
2015Value in Health5 citations Open access
Semantic Scholar
PCV114 DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS
C. Boersma, B. Kappelhoff, M. Postma
20094 citations Open access
Semantic Scholar
Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?
B. Kappelhoff, A. Huitema, J. Beijnen
2005Drugs in R&D3 citations
Semantic Scholar
No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel
B. Kappelhoff, A. Huitema, A. Mairuhu, J. Schellens +1 more
2005Anti-Cancer Drugs2 citations
Semantic Scholar
Problemen bij subcutane toediening van laagmoleculairgewichtheparines na totale heup- en knievervangende operaties
C. Boersma, A. Broer, B. Kappelhoff, J. Brouwers +2 more
20101 citations
Semantic Scholar
Administration Advantages and Cost-Savings with Dabigatran Etexilate Versus Parenteral Agents for Thromboprophylaxis After Major Orthopaedic Surgery in the Netherlands.
C. Boersma, B. Kappelhoff, M. Postma
20091 citations
Semantic Scholar
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals
B. Kappelhoff, A. Huitema, Z. Yalvaç, Jan M. Prins +1 more
20031 citations
Semantic Scholar
Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran
T. Fens, L. D. de Jong, B. Kappelhoff, C. Boersma +1 more
2023Journal of Market Access & Health Policy0 citations Open access
Semantic Scholar
PDG19 Budget and Health Impacts of Switching Atrial Fibrillation Patients to Dabigatran, Taking INR Control, Unique Dosing-Evidence and Product Lifecycle Outcomes Explicitly into Account
C. Boersma, L. D. de Jong, K. Wammes, B. Kappelhoff +2 more
20200 citations Open access
Semantic Scholar
Economic evaluation of dabigatran for the treatment and secondary prevention of venous thromboembolism
J. Stevanović, Dvortsin Evgeni, B. Kappelhoff, M. Voorhaar +1 more
20150 citations
Semantic Scholar
Author response : economic evaluation of dabigatran etexilate.
M. Postma, B. Kappelhoff, M. van Hulst, J. Brouwers
2013Journal of Medical Economics0 citations
Semantic Scholar
The Authors’ Reply
B. Kappelhoff, A. Huitema, J. Beijnen
20050 citations
Semantic Scholar
Clinical pharmacological investigations of antiretroviral drugs
B. Kappelhoff
20050 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Huitema×14
Invite
A. Huitema — researcher profile on SciRah
J. Beijnen×13
Invite
J. Beijnen — researcher profile on SciRah
M. Postma×9
Invite
M. Postma — researcher profile on SciRah
J. Mulder×5
Invite
J. Mulder — researcher profile on SciRah

×4

Invite

F. van Leth — researcher profile on SciRah

P. Meenhorst×4

Invite

P. Meenhorst — researcher profile on SciRah

M. van Hulst×4

Invite

M. van Hulst — researcher profile on SciRah

J. Stevanović×4

Invite

J. Stevanović — researcher profile on SciRah

Invite

C. Boersma — researcher profile on SciRah

T. Macgregor×3

Invite

T. Macgregor — researcher profile on SciRah

Invite

J. Lange — researcher profile on SciRah

K. Crommentuyn×3

Invite

K. Crommentuyn — researcher profile on SciRah